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Aims: Gamma-glutamyl transferase (GGT), an enzyme present on the endothelium, is
involved in the release of nitric oxide (NO) from S-nitrosoglutathione (GSNO) and in the
GSNO-induced vasodilation. Endogenous GSNO is a physiological storage form of NO
in tissues while exogenous GSNO is an interesting candidate for compensating for the
decreased NO bioavailability occurring during cardiovascular diseases. We investigated
in a rat model of human hypertension, the spontaneous hypertensive rat (SHR), submitted
or not to high salt diet, whether a decreased vascular GGT activity modifies the
vasorelaxant effect of GSNO.
Methods: Thoracic aortic rings isolated from male SHR and Wistar Kyoto rats
(WKY) aged 20–22 weeks—submitted or not for 8 weeks to a high salt diet (1% w/v
NaCl in drinking water) were pre-constricted with phenylephrine then submitted to
concentration-vasorelaxant response curves (maximal response: Emax; pD2) to carbachol
or sodium nitroprusside to evaluate endothelial dependent or independent NO-induced
vasodilation, or GSNO (exogenous NO vasodilation depending from the endothelial
GGT activity). GGT activity was measured using a chromogenic substrate in aortic
homogenates. Its role in GSNO-induced relaxation was assessed following inhibition of
the enzyme activity (serine-borate complex). That of protein disulfide isomerase (PDI),
another redox sensitive enzyme involved in GSNO metabolism, was assessed following
inhibition with bacitracin.
Results: Aortic GGT activity (18–23µmol/min/mg of tissue in adult WKY) decreased
by 33% in SHR and 45% in SHR with high salt diet. Emax and pD2 for sodium
nitroprusside were similar in all groups. Emax for carbachol decreased by −14%,
reflecting slight endothelial NO-dependent dysfunction. The GSNO curve was slightly
shifted to the left in SHR and in SHR with high salt diet, showing a small enhanced
sensitivity to GSNO. Involvements of GGT, as that of PDI, in the GSNO effects were
similar in all groups (pD2 for GSNO −0.5 to −1.5 following enzymatic inhibition).
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Conclusion: Hypertension is associated with a decreased aortic GGT activity without
decreasing the vasorelaxant effects of GSNO, whose bioactivity may be supplemented
through the alternative enzymatic activity of PDI.
Keywords: NO-dependent vasorelaxation, Spontaneous Hypertensive Rat, S-nitrosoglutathione, gamma-
glutamyltransferase, aortic ring
INTRODUCTION
Many cardiovascular diseases are associated with a decreased
endothelial-dependent bioavailability of nitric oxide (NO),
leading to impaired vasodilation, pro-inflammatory/oxidative,
pro-proliferative, and pro-thrombotic status (Vanhoutte and
Boulanger, 1995; Le Brocq et al., 2008). Atherosclerosis,
for example, which mainly concerns large conductance
arteries where vasoactive functions depend specifically on
the bioavailability of NO (Luksha et al., 2009) leads to the
use of several NO donors (organic nitrates) for therapeutics.
However, these treatments are known to provide fast NO release
concomitant with induction of oxidative stress and tolerance
(Bauer and Fung, 1991; Parker and Gori, 2001). New NO-
donors, such as S-nitrosothiols have been proposed as interesting
therapeutic alternatives as they do not present the drawbacks of
organic nitrates.
S-nitrosoglutathione (GSNO), the nitrosated form of
glutathione, is currently investigated as NO- donor to restore
NO homeostasis, and is an interesting candidate for therapeutics
as it mimics endogenous GSNO-related functions. Endogenous
cellular formation of GSNO involves either direct reaction of
NO/nitrosating species with GSH, or previous formation of
protein-based or low molecular weight S-nitrosothiols followed
by subsequent transnitrosation to GSH (Al-Sa’doni and Ferro,
2004; Broniowska et al., 2013). The ability of GSNO to transfer
its NO to cystein residue of endogenous peptides or proteins via
dynamic processes of nitrosation/denitrosation (Gaucher et al.,
2013) explains its ability to store and transport NO to sites of
utilization in the body (Wu et al., 2016).
Gamma-glutamyl transferase (GGT) is one of the enzyme
activity implicated in the release of NO from GSNO and
its uptake into the cell (Hogg et al., 1997; Bramanti et al.,
2009). GGT specifically catalyzes endogenous as exogenous
GSNO breakdown producing cysteinylglycine and NO in
endothelial cells. There, either NO diffuses to the smooth muscle
cells to activate the soluble guanylyl cyclase/cyclic guanosine
monophosphate pathway and induce vasorelaxation (Tullett
et al., 2001; Alencar et al., 2003; Heikal et al., 2011), or it reacts
with endothelial glutathione or proteins cysteine residue to form
S-nitrosothiols. Those S-nitrosothiols may release NO through
transnitrosation processes involving enzymes such as the system
thioredoxin/thioredoxin reductase (Marozkina and Gaston,
Abbreviations: EDTA, Ethylenediaminetetraacetic acid; EC50, half
maximal effective concentration; Emax, maximal response; GGT, gamma-
glutamyltransferase; GSH, glutathione; GSNO, S-nitrosoglutathione; NO, nitric
oxide; PDI, protein disulfide isomerase; WKY, Wistar Kyoto rat; WKY-S, high salt
diet submitted Wistar Kyoto rat; SEM, standard error of mean; SHR, spontaneous
hypertensive rat; SHR-S, high salt diet submitted spontaneous hypertensive rat.
2012; Gaucher et al., 2013). We have previously documented that
endothelial GGT is critical for GSNO-dependent NO-delivery
and vasorelaxation in aortic rings isolated from normotensive
rats (Dahboul et al., 2012). In this context, GSNO and its cellular
metabolism enzymes are likely to be involved in blood pressure
regulation (Ishibashi et al., 2011).
In the present study, we evaluated GSNO-induced
vasorelaxation in the Spontaneous Hypertensive Rat (SHR), with
the hypothesis that hypertension may impair GGT activity of
the vessel wall. Therefore, the bioactivity of exogenous treatment
with GSNO would be modified. In the present study, we
analyzed concentration-vasorelaxant response curves (maximal
response Emax and pD2 calculated as –log EC50, the half maximal
effective concentration) to carbachol and sodium nitroprusside
in order to evaluate endothelial dependent and independent
NO-induced vasodilation, and to GSNO (exogenous NO
vasodilation depending from the endothelial GGT activity). As
protein disulfide isomerase (PDI), a membrane enzyme from
the redoxins family, has also been reported to be involved in the
release of NO from GSNO (Heikal et al., 2011), we also evaluated
whether the vasorelaxant effect of GSNO may be warranted
through such alternative enzymatic activity.
MATERIALS AND METHODS
Chemicals
All reagents were of analytical grade. Carbachol, phenylephrine,
L-γ-glutamyl-3-carboxy-4-nitroanilide, and all other reagents
were obtained from Sigma-Aldrich (Saint Quentin Fallavier,
France). Ultrapure deionized water (18.2 M.cm) was used to
prepare all solutions. Standard solutions of GSNO were prepared
by nitrosation of glutathione after mixing glutathione with
sodium nitrite (ration 1:1) in acidic medium according to the
method previously described (Parent et al., 2013).
The purity of GSNO was assessed by ultraviolet
spectrophotometry using its molar absorbance at 334 nm
(ε= 922 M−1.cm−1).
Rats and Ethical Statements
All experiments were performed in accordance with the
European Parliament guidelines (2010/63/EU) for the use of
experimental animals and the respect of the 3 Rs’ requirements
for Animal Welfare. The protocols and procedures were
approved by the advisory regional ethical committee on
animal experiments: Comité d’Ethique Lorrain en Matière
d’Expérimentation Animale, CELMEA protocol agreement N◦
02420.03.
Young adult normotensive Wistar-Kyoto rats (WKY) or
SHR (11 weeks-old, 300–325 g) were purchased from Janvier
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Laboratories (Le Genest St Isle, France), kept under standard
conditions (temperature: 21 ± 1◦C, hygrometry 60 ± 10%,
light on 6 a.m. to 6 p.m.) and ate standard diet (A04,
Safe, Villemoisson-sur-Orge, France) and drank water (reverse
osmosis system, Culligan, Brussels, Belgium) ad libitum. After
1 week, they were randomly separated into two series: 20–22
weeks-old adult SHR and WKY (WKY/SHR), 20–22 weeks-old
adult SHR and WKY rats submitted to a high salt diet (WKY-
S/SHR-S) to impair endothelial-dependent vasodilation (Kagota
et al., 2001). In high salt diet groups, salt was incorporated at 1%
(w/v) in drinking water for 8 weeks from the age of 12–14 weeks.
Mean body weight was 417 ± 9 and 418 ± 9 g in WKY/SHR,
399± 9 and 394± 9 g inWKY-S/SHR-S. Themean systolic blood
pressure was measured by the tail-cuff method (149 ± 5 and
225 ± 10 mmHg in WKY/SHR; 161 ± 9 and 256 ± 9 mmHg
in WKY-S/SHR-S).
Rats were anesthetized with sodium pentobarbitone
(60mg.kg−1, intraperitoneal injection, Sanofi Santé Nutrition
Animale, Libourne, France) and the adequacy of anesthesia
was checked by testing the loss of the corneal and pinch paw
withdrawal reflexes. If a change in the reflexes occurred, a bolus
of sodium pentobarbitone was immediately administered. After
administration of heparin (1000 IU.kg−1 heparine Choay, penis
vein), rats were sacrificed by exsanguination and segments (3
cm) of the descending thoracic aorta were removed. Vessels were
cleaned from surrounding connective tissues, cut into 2-mm
long rings (8 rings per rat) and immediately used for vasoactivity.
Some samples of aortic rings were frozen in liquid nitrogen and
kept at−80◦C until biochemical studies were analyzed.
Vasorelaxation Studies
Vasorelaxation was evaluated on endothelium-intact aortic rings
(Dahboul et al., 2012). Aortic vasoactivity was measured using
an isometric tension recording system in 10mL organ chambers
(EMKABATH, Emka Technology, France). All manipulations
and assays involving GSNO were performed under conditions of
subdued light, in order to minimize light-induced degradation.
The bath was filled with Krebs’ solution containing 119mM
NaCl, 4.7mM KCl, 1.2mM KH2PO4, 1.2mM MgSO4, 1.6mM
CaCl2, 24mM NaHCO3, 5.5mM glucose, adjusted to pH 7.4
(10mL, 37◦C) and continuously bubbled with 95% O2 and
5% CO2. Following 60-min equilibration with a basal resting
tension determined at 2 g, rings were exposed two times to KCl
(60mM, 5min). Aortic rings (n = 7–19 per group, from 4 to 11
different rats in each group) were then preconstricted with 10−6
M phenylephrine. At the plateau of contraction, concentration-
relaxation response curves to increasing concentrations of GSNO
(10−10 to 3.10−5 M) were performed.
The roles of GGT and PDI were assessed by inhibiting their
activity with competitive reversible inhibitors, the serine-borate
complex (20mM) or bacitracin (200µM), respectively (Dahboul
et al., 2012).
Endothelial dependent and independent NO-induced
vasodilation were evaluated by measuring the ability for
preconstricted aortic rings to relax following, respectively,
administration of carbachol, a muscarinic acetylcholine
receptors agonist, and sodium nitroprusside, an endothelial
independent NO-release drug. Decreases in maximal response
(Emax) to carbachol (10−10 to 10−5 M response curves) witness
endothelial NO-related dilating dysfunction, while changes in
sodium nitroprusside concentration response curves reflects
dysfunction in smooth muscle cell contractile machinery (Kreye
et al., 1975; Boulanger et al., 1994).
GGT Activity in Aorta
GGT activity was measured spectrophotometrically after
hydrolysis of the synthetic GGT substrate L-γ-glutamyl-3-
carboxy-4-nitroanilide as previously described (PetitClerc et al.,
1980). Briefly, aortic rings were homogenized and incubated for
2 h at 37◦C in Tris buffer (100mM, pH 7.4) containing 1 mM
L-γ-glutamyl-3-carboxy-4-nitroanilide, 20 mM glycylglycine,
and 10 mMMgCl2. After centrifugation at 42,000× g for 10 min
at 4
◦
C, supernatant absorbance was read at 405 nm to monitor
the release of 5-amino-2-nitrobenzoate (ε = 9500 M−1.cm−1)
from L-γ-glutamyl-3-carboxy-4-nitroanilide. Enzyme activities
are expressed in nmol of 5-amino-2-nitrobenzoate per min per g
of tissue.
Glutathione Content in Aorta
The assay was based on the use of 2,3-
naphthalenedicarboxyaldehyde, a glutathione- fluorogenic
probe, as previously described (Maguin Gaté et al., 2011).
Briefly, thoracic aortic tissue was homogenized in cold 10% (v/v)
perchloric acid containing 5 mM EDTA. After centrifugation
(14,000 × g for 5 min at 4◦C), the acidic supernatants
were neutralized with 10 M of NaOH and samples were
transferred to a 96-well microtiter plate (Nunc, black model
B23806). Then, 0.4 M borate buffer (pH 9.2) and 5.4 mM
2,3-naphthalenedicarboxyaldehyde solution were added into
each well and the fluorescence intensity of glutathione-2,3-
naphthalenedicarboxyaldehyde adduct was measured within 15
min by using a microplate reader (λexc = 485 ± 20 nm, λem
= 528 ± 20 nm, Synergy 2 mode, Biotek Instruments, Colmar,
France). The glutathione content in samples was calculated
from the calibration curve equation, and expressed as nmol
glutathione per g of wet tissue.
Data Analysis and Statistical Tests
Relaxant responses of GSNO, sodium nitroprusside or carbachol
were given as the percentage of 10−6 M phenylephrine
precontraction and calculated as:
% relaxation =


(
Tension
(
PHE 10−6M, g
)
− Tension(
GSNO, nitroprusside or carbachol, g
))
(
Tension
(
PHE 10−6, g
)
− Tension
(
BASELINE, g
))

× 100
The half maximal effective concentration (EC50) and maximal
response (Emax) were calculated by fitting each individual
concentration response curve using the Hill logistic equation
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(Graph Pad prism R© software version 5.0):
% relaxation = Emin +
(Emax − Emin)(
1+ 10((logEC50 − concentration)×Hill slope)
)
where Emin and Emax = minimal and maximal response reached
in each concentration-response curve.
The pD2 was calculated as−log EC50.
After modeling individual concentration response curve,
means ± S.E.M. of Emax and pD2 were analyzed by a Student
t-test (adult SHR compared to WKY; SHR-S to WKY-S). We
also performed two-ways (hypertension, concentration) ANOVA
analysis followed by a post-hoc Bonferroni test to compare
individual concentrations. The null hypothesis was rejected at
p< 0.05.
RESULTS
Thoracic aortic activity of GGT and glutathione content of the
aortic wall decreased both by 33% in SHR and by 45 and 53% in
SHR-S (Figure 1).
Each individual concentration response curve to sodium
nitroprusside, carbachol and GSNO fitted the Hill model.
Responses (Emax and pD2) to sodium nitroprusside were similar
in all groups (Table 1). Neither Emax nor pD2 for carbachol
changed in SHR compared toWKY. Emax for carbachol decreased
by 14% in high salt diet SHR (p< 0.05 vs.WKY-S) with no change
in pD2 (Figure 2).
Concentration response curves to GSNO did not show any
decrease in Emax with hypertension alone nor with high salt
diet as compared to their corresponding control WKY. The
FIGURE 1 | Influence of hypertension and/or salt diet on aortic GGT
activity and aortic glutathione content. Thoracic aortic GGT activity (A,B)
and aortic glutathione content (C,D) in WKY/SHR rats submitted
(SHR-S/WKY-S; B,D) or not (A,C) to high-salt diet 1% (w/v) during 8 weeks.
*p < 0.05 Student t-test vs. WKY of the same series. n = 3–4 aortic rings per
group, isolated from 4 different rats per group.
concentration response curves were even slightly shifted to lower
concentrations of GSNO in SHR (pD2 + 0.4) and SHR-S (pD2
+ 0.5) vs. WKY and WKY-S, respectively (Figure 3). In the
presence of serine borate complex (an inhibitor of GGT), or in the
presence of bacitracin (an inhibitor of PDI), the concentration
response curves to GSNO were shifted to the right in all groups
as shown by the significant decreases in pD2 (−0.5 to −1.5 log)
(Figure 4).
DISCUSSION
In SHR and SHR-S of the present study, muscle cells dilation
capacities (responses to sodium nitroprusside) were maintained,
while endothelial NO-dependent vasodilation started to decrease
in SHR-S. Aortic GGT activity decreased in SHR and SHR-
S, but this did not impair the capacity of GSNO to
relax isolated aortic rings. The pD2 values for GSNO even
increased.
To our knowledge, this is one of the few study, with that of
Yilmaz et al., to address the possibility that impairment of NO
TABLE 1 | Influence of hypertension and/or salt diet on the vasorelaxant
responses to sodium nitroprussiate.
WKY SHR WKY-S SHR-S
Sodium nitroprussiate pD2 7.8 ± 0.2 8.3 ± 0.4 8.2 ± 0.2 8.4 ± 0.2
Emax,% 109 ± 3 111 ± 4 108 ± 5 112 ± 3
Emax and pD2 values obtained from cumulative concentration response curves with
sodium nitroprusside in phenylephrine pre-constricted aortic rings isolated from WKY
et SHR submitted or not to high-salt diet 1% (w/v) during 8 weeks (SHR/WKY and
SHR-S/WKY-S). n = 4–7 aortic rings per group, isolated from 3 different rats per group.
FIGURE 2 | Influence of hypertension and/or salt diet on the
vasorelaxant responses to carbachol. Cumulative concentration response
curves to carbachol of phenylephrine pre-constricted aortic rings isolated
from: (A) adult SHR/WKY rats and (B) adult SHR/WKY rats submitted to
high-salt diet 1% (w/v) during 8 weeks (SHR-S/WKY-S). *p < 0.05 Student
t-test vs. WKY or WKY-S of the same series following the Hill analysis. #p <
0.05 vs. WKY or WKY-S at the same concentration, two-way analysis of
variance (ANOVA) + Bonferroni post-test. n = number of aortic rings per
group, isolated from 4 to 8 different rats per group.
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FIGURE 3 | Influence of hypertension and/or salt diet on the
vasorelaxant responses to GSNO. Cumulative concentration response
curves to GSNO of phenylephrine pre-constricted aortic rings isolated from:
(A) adult SHR/WKY rats and (B) adult SHR/WKY rats submitted to high-salt
diet 1% (w/v) during 8 weeks (SHR-S/WKY-S). *p < 0.05 Student t-test vs.
WKY or WKY-S of the same series following the Hill analysis. #p < 0.05 vs.
WKY or WKY-S at the same concentration, two-way analysis of variance
(ANOVA) + Bonferroni post-test. n = number of aortic rings per group,
isolated from 6 different rats per group.
homeostasis might be related to alterations in plasma (Yilmaz
et al., 2013) or in vessel wall GGT activity.
The degree of severity of endothelium dependent NO
release vasodilation is commonly evaluated by a decrease in
the response to endothelial muscarinic receptor stimulated by
carbachol or acetylcholine, in the absence of any modification
of the endothelial independent NO vasodilation (no change in
response to nitroprusside, as observed in the present study).
The extremely abundant literature using such experimental
approaches interprets endothelial NO-dependent dysfunction
on the basis of a decrease in either pD2 or Emax or both
(Duarte et al., 2001; Demougeot et al., 2005; Bagnost et al.,
2008; Kane et al., 2010; Isabelle et al., 2012). In the present
study, as those of Isabelle et al. (2012) or Demougeot et al.
(2005), 20-week-old adult SHR did not show any decrease in
maximal effect for carbachol nor acetylcholine. In salt-treated
SHR of the present study, endothelium dependent NO release
vasodilation was weak with a −14% decrease in Emax for
carbachol. It has to be noticed that global endothelial dysfunction
in SHR not only involves decreased NO bioavailability but also
decreased production of endothelium-hyperpolarizing factor and
prostacyclin (Deanfield et al., 2005; Schini-Kerth et al., 2011),
higher production of endothelium-dependent vasoconstrictive
agents (Touyz and Schiffrin, 2004; Félétou et al., 2009) and
possible long term structural changes (Touyz and Schiffrin, 2004;
Lee and Griendling, 2008). For other cardiovascular diseases,
such as atherosclerosis, the prominent feature for endothelial
dysfunction lies on the reduction in NO bioavailability, which
is regarded as a major factor in the pathogenesis of the disease
(Mudau et al., 2012; Jensen and Mehta, 2016; Vanhoutte et al.,
2016).
Several recent studies have implicated the GGT activity in
cardiovascular diseases. In particular, increased levels of GGT
in serum have been correlated with hypertension (Mason et al.,
FIGURE 4 | Impact of serine-borate complex and bacitracin on
GSNO-induced vasorelaxations. Cumulative concentration response
curves to GSNO in the presence of serine-borate complex (20 mM) or
bacitracin (200 µM) in phenylephrine pre-constricted aortic rings isolated from
(A) SHR/WKY rats and (B) SHR/WKY rats submitted to high-salt diet 1% (w/v)
during 8 weeks (SHR-S/WKY-S). *p < 0.05 Student t-test vs. WKY or WKY-S
of the same series following the Hill analysis. #p < 0.05 vs. GSNO alone of
the same group, Student t-test, n = number of aortic rings per group, isolated
from 4 to 11 different rats per group.
2010) as well as with impaired aortic elasticity in prehypertensive
patients (Celik et al., 2010). As GGT is implicated in GSNO
catabolism and NO release (Hogg et al., 1997; Bramanti et al.,
2009), it is possible that increasing levels of serum GGT may
reduce the bioavailability of GSNO in blood, thus hampering its
peripheral utilization for regulation of vascular tone. We have
previously shown that increasing levels of GGT activity in blood
do correspond to increased rates of clearance of exogenously
added GSNO (Bramanti et al., 2009). Another study conducted
in patients with chronic kidney disease showed increased serum
GGT activity in association with endothelial dysfunction (Yilmaz
et al., 2013).
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Besides the soluble enzyme found in serum, GGT is also
present at cellular level in vascular tissues. Substantial levels of
the enzyme are expressed in arterial endothelium (Cotgreave
and Schuppe-Koistinen, 1994). We have previously shown that
such GGT activity is involved in the utilization of GSNO, in
that it promotes the local release of NO from GSNO thus
mediating its vasorelaxant effect (Dahboul et al., 2012). In
atherosclerotic lesions, GGT was found to accumulate in plaques,
in association with cells of the macrophagic lineage as well
as with the lipid core (Paolicchi et al., 2004; Franzini et al.,
2009). This accumulation may derive both from insudation
of circulating GGT and from cellular macrophages dependent
release of GGT.Moreover, several GGT fractionsmay be involved
(Franzini et al., 2008). Finally, the relationship between tissue
and circulating GGT are complex, especially in a pathological
environment associating inflammation (atherosclerosis) and/or
oxidative stress (present).
A loss of GGT activity was described in endothelial
cells submitted to oxidative stress (Muruganandam et al.,
2011). Therefore, the pro-oxidant environment associated with
hypertension, as witnessed by the 33–53% fall in aortic wall
glutathione content in SHR and SHR-S, could participate
in the decrease in aortic wall GGT activity we observed.
However, this decrease in aortic wall GGT activity did
not impair the vasorelaxant effect of GSNO. Furthermore,
GSNO-mediated vasodilation was still dependent on GGT,
as shown by our experiments under inhibition with serine-
borate complex. This suggests that (i) even if it decreases, the
GGT activity remains sufficient to maintain GSNO vasorelaxant
effect and/or (ii) other pathway of GSNO bioactivation are
substituting for GGT. Membrane PDI, a membrane enzyme
from the redoxins family, which is involved in the release of
NO from GSNO, and in GSNO vasorelaxant effect (Heikal
et al., 2011), increases its expression under oxidative stress
(Janiszewski et al., 2005; Gaucher et al., 2013). SHR of the
present study developed oxidative stress (decreased GSH content,
Figure 1) (e.g., through upregulation of NOX; Tabet et al.,
2008; Montezano and Touyz, 2012). Moreover, inhibition of
PDI with bacitracin decreased the pD2 values of GSNO in
SHR and SHR-S demonstrating that the vasorelaxant effect of
GSNO was dependent on PDI. Therefore, the decreased GGT
activity occurring during hypertension may be balanced by
an oxidative stress-related increase in PDI expression and/or
activity, slightly improving vasorelaxant effects of GSNO in SHR
and SHR-S.
One limitation of this study relies on the use of bacitracin.
Bacitracin is not a specific inhibitor of PDI, which displays several
activities (oxidoreductase, chaperone, and isomerase, Khan and
Mutus, 2014). However, most of those activities are involved in
the release of NO from GSNO (Shah et al., 2007).
CONCLUSION
In conclusion, our data suggest that hypertension is accompanied
by a decreased activity of aortic GGT, one of the enzymes
catalyzing the release of bioactive NO from GSNO. Nevertheless,
vasorelaxation induced by GSNO is slightly improved. We
suggest that under hypertension and oxidative stress, GSNO
effect is likely warranted by the concomitant action of PDI, the
other major (oxidative stress-inducible) enzyme involved in NO
release from GSNO.
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